maveropepimut-S (MVP-S) / BioVaxys 
Welcome,         Profile    Billing    Logout  
 19 Diseases   8 Trials   8 Trials   237 News 
11 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
maveropepimut-S (MVP-S) / BioVaxys
AVALON, NCT05243524 / 2022-003666-20: Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer

Terminated
2b
16
Canada, US
Maveropepimut-S, MVP-S, DPX-Survivac, Cyclophosphamide 50mg, CPA, Procytox, Cytoxan
ImmunoVaccine Technologies, Inc. (IMV Inc.), Immunovaccine Technologies Inc. (IMV Inc.)
Platinum-resistant Epithelial Ovarian Cancer
07/23
08/23
VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting
2b
102
Europe, Canada, US, RoW
DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan
ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC
Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma
10/24
04/25
2009-017798-39: An open label, Phase II study of vaccination with Survivin peptides emulsified in Montanide ISA 51VG after IMP 321 injection in prostate carcinoma patients with biochemical failure (PROVAX study)

Ongoing
2
20
Europe
SURVIVAC, IMP321, EMD 640744, Powder for solution for injection, Solution for injection
ISTITUTO NAZIONALE PER LA CURA TUMORI
Prostate cancer, biochemical failure after all potentially curative standard local therapies (radiotherapy, brachytherapy and surgery) or biochemical progression while patients have castrated levels of testosterone or after first-line anti hormonal therapy
 
 
2013-005387-25: no

Ongoing
2
10
Europe
DPX-Survivac, Solution for injection, DPX-SURVIVAC
Sapienza, University of Rome, Sapienza, University of Rome
Glioblastoma is the most common primary brain tumour in humans withthe most severe prognosis. Standard treatments consist primarily ofsurgery in order to debulk thetumoral mass, as well asradiochemotherapy to induce optimal local tumor control. However themedian overall survival (OS)is about 15 months, with 88% of patientsdead within 3 years il glioblastoma è il tumore cerebrale più diffuso, associato ad unaprognosi infausta. I trattamenti standard sono rappresentati dallachirurgia che permette di eradicare la massa tumorale e la radiochemioterapiaper il controllo della crescita tumorale. La sopravvivenzamedia è di circa 15 mesi, con l'88% di decessi entro i 3 anni., Glioblastoma is a malignant brain tumor, invasive, fast-growing and poorprognosis. Glioblastoma can be of primitive type or manifest as theprocessing of other brain tumors (secondary type). il glioblastoma è un tumore maligno del cervello, invasivo, a rapidacrescita e prognosi infausta. può essere di tipo primitivo o manifestarsicome trasformazione di altri tumori cerebrali., Diseases [C] - Cancer [C04]
 
 
SPiReL, NCT03273582: DPX-Survivac and Checkpoint Inhibitor in DLBCL

Not yet recruiting
2
25
NA
DPX-Survivac, Pembrolizumab, Cyclophosphamide 50mg
Sunnybrook Health Sciences Centre, ImmunoVaccine Technologies, Inc., Merck Sharp & Dohme Corp.
Diffuse Large Cell Lymphoma, Recurrent, Adult, Refractory Diffuse Large B-Cell Lymphoma
05/20
05/21
SPiReL, NCT03349450: DPX-Survivac and Checkpoint Inhibitor in DLBCL

Checkmark Top-line data from SPiReL trial in combination with DPX-Survivac for r/r DLBCL
Nov 2020 - Nov 2020: Top-line data from SPiReL trial in combination with DPX-Survivac for r/r DLBCL
Checkmark From SPiReL trial in combination with DPX-Survivac for r/r DLBCL at ASH 2019
Dec 2019 - Dec 2019: From SPiReL trial in combination with DPX-Survivac for r/r DLBCL at ASH 2019
Checkmark Updated data from SPiReL trial in combination with DPX-Survivac
More
Completed
2
25
Canada
DPX-Survivac, Pembrolizumab, Cyclophosphamide 50mg
Sunnybrook Health Sciences Centre, ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC
Adult Diffuse Large Cell Lymphoma, Recurrent, Adult Refractory Diffuse Large B-Cell Lymphoma
10/21
07/23
2022-003666-20: DPX-Survivac and Low-Dose Cyclophosphamide in Participants with Platinum-Resistant, Epithelial Ovarian Cancer (AVALON)

Not yet recruiting
2
73
Europe
Maveropepimut-S (formerly DPX- Survivac), Cyclophosphamide, Powder and solvent for solution for injection, Tablet, Cyclophosphamide Tablets 50 mg
Immunovaccine Technologies Inc. (IMV Inc.), Immunovaccine Technologies Inc. (IMV Inc.)
Platinum Resistant Epithelial Ovarian Cancer, Platinum Resistant Ovarian Cancer, Diseases [C] - Cancer [C04]
 
 
PESCO, NCT03029403: Phase 2 Study of Pembrolizumab, DPX-Survivac Vaccine and Cyclophosphamide in Advanced Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Active, not recruiting
2
47
Canada
Pembrolizumab, Keytruda, DPX-Survivac, Cyclophosphamide, Procytox
University Health Network, Toronto, Merck Sharp & Dohme LLC, ImmunoVaccine Technologies, Inc. (IMV Inc.)
Advanced Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
12/24
02/25
KEYNOTE 903, NCT03836352: Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors

Active, not recruiting
2
184
Canada, US
DPX-Survivac, Cyclophosphamide, Pembrolizumab, MK-3475
ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC
Ovarian Cancer, Hepatocellular Carcinoma, Non-small Cell Lung Cancer, Bladder Cancer, Microsatellite Instability-High
12/23
12/23
DeCidE1, NCT02785250: Study of DPX-Survivac Therapy in Patients With Recurrent Ovarian Cancer

Checkmark Top-line data from DeCidE1 trial in combination with DPX-Survivac
Feb 2020 - Feb 2020: Top-line data from DeCidE1 trial in combination with DPX-Survivac
Checkmark Top-line data from trial in combination with DPX-Survivac at ASCO 2018
Jun 2018 - Jun 2018: Top-line data from trial in combination with DPX-Survivac at ASCO 2018
Active, not recruiting
1b/2
85
Canada, US
DPX-Survivac, Cyclophosphamide, Epacadostat (INCB024360)
ImmunoVaccine Technologies, Inc. (IMV Inc.), Incyte Corporation
Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Peritoneal Cancer
10/20
05/25
NCT04895761: Neoadjuvant DPX-Survivac Aromatase Inhibition, Radiotherapy or Cyclophosphamide in HR+HER2- Breast Cancer

Active, not recruiting
1
6
US
DPX-Survivac, Letrozole 2.5mg, Femara, Cyclophosphamide 50mg, cytoxan, XRT 10Gy x2
Providence Health & Services
Breast Cancer
06/23
09/26

Download Options